Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tom Decroo

Showing results (1-10 of 138) with videos related to

Pageof 14
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 20, 2020
How Second-Line Injectable Drugs WorkArmand Van Deun, Tom Decroo
Journal of Clinical Tuberculosis and Other Mycobacterial Diseases|June 7, 2021
Should treatment of low-level rifampicin mono-resistant tuberculosis be different?Armand Van Deun, Tom Decroo
The Lancet. Infectious Diseases|January 29, 2022
Implications of bedaquiline-resistant tuberculosisTom Decroo, Armand van Deun
The Lancet. Global Health|August 9, 2014
Lifelong ART for 20 million people in sub-Saharan Africa: communities will be key for successTom Decroo, Nathan Ford, Marie Laga
Public Health Action|July 27, 2017
What was the effect of the West African Ebola outbreak on health programme performance, and did programmes recover?Tom Decroo, Gabriel Fitzpatrick, Jackson Amone
The Lancet. Infectious Diseases|June 16, 2024
Longevity of modified standard short treatment regimens for rifampicin-resistant tuberculosisTom Decroo, Anita Mesic, Ine Decuyper
F1000Research|June 25, 2019
Operational research: did health systems in Sierra Leone recover after the 2014-15 Ebola outbreak?Tom Decroo, Alexandre Delamou, John C Reeder
The Journal of Antimicrobial Chemotherapy|January 3, 2018
Comment on: Effects of isoniazid resistance on TB treatment outcomes under programmatic conditions in a high-TB and -HIV setting: a prospective multicentre studyTom Decroo, Armand Van Deun, Lutgarde Lynen
Lancet (London, England)|June 20, 2015
Favipiravir--a prophylactic treatment for Ebola contacts?Michel Van Herp, Hilde Declerck, Tom Decroo
Journal of Clinical Tuberculosis and Other Mycobacterial Diseases|March 12, 2024
Relapse after treatment with standardized all-oral short regimens for rifampicin-resistant tuberculosis (RR-TB): A systematic review and <i>meta</i>-analysisAhmad Reza Yosofi, Anita Mesic, Tom Decroo
Pageof 14

Showing results (1-10 of 138) with videos related to

Sort By:
Pageof 14
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 20, 2020
How Second-Line Injectable Drugs WorkArmand Van Deun, Tom Decroo
Journal of Clinical Tuberculosis and Other Mycobacterial Diseases|June 7, 2021
Should treatment of low-level rifampicin mono-resistant tuberculosis be different?Armand Van Deun, Tom Decroo
The Lancet. Infectious Diseases|January 29, 2022
Implications of bedaquiline-resistant tuberculosisTom Decroo, Armand van Deun
The Lancet. Global Health|August 9, 2014
Lifelong ART for 20 million people in sub-Saharan Africa: communities will be key for successTom Decroo, Nathan Ford, Marie Laga
Public Health Action|July 27, 2017
What was the effect of the West African Ebola outbreak on health programme performance, and did programmes recover?Tom Decroo, Gabriel Fitzpatrick, Jackson Amone
The Lancet. Infectious Diseases|June 16, 2024
Longevity of modified standard short treatment regimens for rifampicin-resistant tuberculosisTom Decroo, Anita Mesic, Ine Decuyper
F1000Research|June 25, 2019
Operational research: did health systems in Sierra Leone recover after the 2014-15 Ebola outbreak?Tom Decroo, Alexandre Delamou, John C Reeder
The Journal of Antimicrobial Chemotherapy|January 3, 2018
Comment on: Effects of isoniazid resistance on TB treatment outcomes under programmatic conditions in a high-TB and -HIV setting: a prospective multicentre studyTom Decroo, Armand Van Deun, Lutgarde Lynen
Lancet (London, England)|June 20, 2015
Favipiravir--a prophylactic treatment for Ebola contacts?Michel Van Herp, Hilde Declerck, Tom Decroo
Journal of Clinical Tuberculosis and Other Mycobacterial Diseases|March 12, 2024
Relapse after treatment with standardized all-oral short regimens for rifampicin-resistant tuberculosis (RR-TB): A systematic review and <i>meta</i>-analysisAhmad Reza Yosofi, Anita Mesic, Tom Decroo
Pageof 14